stockmarketproxy
/
BMYNYSE,NYSESEC EDGAREDGAR

BRISTOL MYERS SQUIBB CO

Pharmaceutical Preparations·PRINCETON, NJ·FY end 12/31·CIK 14272
OverviewFinancialsCompensationGovernanceInsidersFilings

Financials

5-year history · USD
MetricFY 2025FY 2024FY 2023FY 2022FY 2021Trend
Revenue$48.2B$48.3B$45.0B$46.2B$46.4B
Gross Profit——————
Operating Income——————
Net Income$7.1B-$8.9B$8.0B$6.3B$7.0B
Operating CF$14.2B$15.2B$13.9B$13.1B$16.2B
Capex$1.3B$1.2B$1.2B$1.1B$973.0M
Free Cash Flow$12.8B$13.9B$12.7B$11.9B$15.2B
Buybacks$0$0$5.2B$8.0B$6.3B
Dividends——————
Gross Margin——————
Operating Margin——————
Net Margin14.6%-18.5%17.8%13.7%15.1%
FCF Margin26.7%28.9%28.1%25.9%32.8%
R&D / Revenue20.6%23.1%20.7%20.6%24.5%
Effective Tax24.4%-6.6%4.7%17.7%13.4%
Debt / Equity4.755.942.592.382.34
Buybacks / FCF0.0%0.0%40.7%67.0%41.3%

Peer comparison

Pharmaceutical Preparations · 5 peers
CEO Pay Ratio
BMY
131:1
ROIV
518:1
AXSM
23:1
COGT
95:1
PFE
277:1
ABT
166:1
CEO total comp
BMY
—
ROIV
$163M
AXSM
$34M
COGT
$28M
PFE
$28M
ABT
$24M
Net Margin
BMY
14.6%
ROIV
-592.0%
AXSM
-28.7%
COGT
—
PFE
12.4%
ABT
14.7%